Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?

Annals of Hematology

Volumn 91, Issue 9, 2012, Pages 1371-1381

  Efficace, Fabio ^a   Breccia, Massimo ^b   Saussele, Susanne ^c   Kossak Roth, Ute ^c   Cardoni, Annarita ^a   Caocci, Giovanni ^d   Chie, Weichu ^e   Naeem, Adel ^f   Nicolatou Galitis, Ourania ^g   Cocks, Kim ^h   Vignetti, Marco ^a   Baccarani, Michele ⁱ   Mandelli, Franco ^a   Sprangers, Mirjam ^j  

^a GIMEMA Data Center   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF BAGHDAD   (Iraq)

^g UNIVERSITY OF ATHENS   (Greece)

^h UNIVERSITY OF YORK   (United Kingdom)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

Chronic myeloid leukemia; Quality of life; Targeted therapies

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; COPING BEHAVIOR; FATIGUE; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; SEMI STRUCTURED INTERVIEW; SOCIAL SUPPORT; SWELLING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANXIETY; EDEMA; EUROPE; FATIGUE; FEMALE; HEALTH PERSONNEL; HUMANS; IRAQ; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUSCLE CRAMP; PATIENTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL SUPPORT; TAIWAN; YOUNG ADULT;

EID: 84864953426     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1458-6     Document Type: Article

References (23)

1. Kris MG, Benowitz SI, Adams S et al (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28 (36):5327-5347
2. Cortes JE, Jones D, O'Brien S et al (2010) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404
3. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251-2259
4. Kantarjian HM, Giles FJ, Bhalla KN et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141-1145
5. Efficace F, Cocks K, BrecciaMet al (2012) Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 81(2):123-135
6. National Cancer Institute (2006) The NCI Strategic Plan for Leading the Nation. To Eliminate the Suffering and Death due to Cancer. National Institutes of Health Publication No 06-5773 http://strategi cplan.nci.nih.gov/pdf/nci-2007- strategic-plan.pdf. Accessed 15 Mar 2012
7. de Haes JC (1988) Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C (eds) Psychosocial oncology. Pergamon Press, Oxford, pp 61-70
8. Hochhaus A (2011) Managing chronic myeloid leukemia as a chronic disease. American Society of Hematology Educational Program Book. Hematology 2011:128-135. doi:10.1182/ashedu cation-2011.1.128
9. Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving longterm therapy with imatinib compared with the general population. Blood 118(17):4554-4560
10. Johnson C, Aaronson N, Blazeby JM et al (2011) EORTC guidelines for developing questionnaire modules. EORTC Publication, Brussels
11. Basch E, Bennett A, Pietanza MC (2011) Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103(24):1808-1810
12. Harris K, Chow E, Zhang L et al (2009) Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 45(14):2510-2518
13. US Food and Drug Administration (2009) Guidance for Industry: patient-reported outcomemeasures: Use inmedical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration December.http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf. Accessed 15 Mar 2012
14. Laugsand E, Sprangers M, Bjordal K et al (2010) Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcome 8:104
15. Edelman EJ, Gordon K, Justice AC (2011) Patient and providerreported symptoms in the post-cARTera. AIDS Behav 15(4):853-861
16. Nazha A, Williams LA, Kantarjian H et al (2011) Fatigue in chronic myelogenous leukemia patients (pts) treated with tyrosine kinase inhibitors (TKI). Blood (ASH Annual Meeting Abstracts) 118, Abstract 3785
17. Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381-2388
18. Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688-697
19. Savage DG, Szydlo RM, Goldman (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96:111-116
20. Sneeuw KC, Sprangers MA, Aaronson NK (2002) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55 (11):1130-1143
21. Petersen MA, Larsen H, Pedersen L et al (2006) Assessing healthrelated quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42(8):1159-1166
22. Gambacorti-Passerini C, Antolini L, Mahon F-X et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103 (7):553-561
23. Efficace F, Breccia M, Saussele S, et al (2011) International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118: Abstract 3132